Journal article icon

Journal article

Viral vectors as vaccine platforms: deployment in sight.

Abstract:
A little more than a decade after the explosion of research into recombinant live-attenuated or replication-deficient viruses as vaccine platforms, many viral vector-based vaccines have been licensed for animals. Progress has been slower for humans but 2011 will see the licensure of the first viral-vectored vaccine for humans, against Japanese Encephalitis. In addition a vaccine with a viral-vectored component showed efficacy against HIV infection in humans. Viral-based vaccines have an excellent safety profile but must deal with the potential problem of pre-existing anti-vector immunity. Recent successes reflect diverse improvements such as development of new adenovirus serotypes and better prime-boost approaches, suggesting that many viral vectors are approaching their final years as vaccine 'candidates' rather than vaccines.
Publication status:
Published

Actions

Access Document

Publisher copy:
10.1016/j.coi.2011.03.006

Authors

More by this author
Institution:
University of Oxford
Division:
MSD
Department:
NDM
Role:
Author
More by this author
Institution:
University of Oxford
Division:
MSD
Department:
NDM
Sub department:
Jenner Institute
Role:
Author


Journal:
Current opinion in immunology More from this journal
Volume:
23
Issue:
3
Pages:
377-382
Publication date:
2011-06-01
DOI:
EISSN:
1879-0372
ISSN:
0952-7915


Language:
English
Keywords:
Pubs id:
pubs:134990
UUID:
uuid:9c61cc4e-38d7-48c5-b388-4968fb5a7085
Local pid:
pubs:134990
Source identifiers:
134990
Deposit date:
2012-12-19
ARK identifier:

Terms of use


Views and Downloads

Views and downloads will return soon






If you are the owner of this record, you can report an update to it here: Report update to this record

TO TOP